ATMIN

Summary

ATMIN (ATM interactor, HGNC:29034) is a protein-coding gene on chromosome 16q23.2, encoding ATM interactor (O43313). Transcription factor. It is a selective cancer dependency (DepMap: 15.5% of cell lines).

Enables dynein complex binding activity. Involved in positive regulation of DNA-templated transcription. Located in nuclear body.

Source: NCBI Gene 23300 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 178 total — 1 pathogenic, 1 likely-pathogenic
• Cancer dependency (DepMap): dependent in 15.5% of screened cell lines
• MANE Select transcript: NM_015251

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29034
Approved symbol	ATMIN
Name	ATM interactor
Location	16q23.2
Locus type	gene with protein product
Status	Approved
Aliases	ASCIZ, KIAA0431, ZNF822
Ensembl gene	ENSG00000166454
Ensembl biotype	protein_coding
OMIM	614693
Entrez	23300

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000299575, ENST00000539819, ENST00000562969, ENST00000564241, ENST00000565237, ENST00000566488, ENST00000946484

RefSeq mRNA: 2 — MANE Select: NM_015251 NM_001300728, NM_015251

CCDS: CCDS32494, CCDS73917

Canonical transcript exons

ENST00000299575 — 4 exons

Exon	Start	End
ENSE00001298724	81035842	81036206
ENSE00002588712	81043161	81047350
ENSE00003584890	81042281	81042480
ENSE00003590968	81041356	81041481

Expression profiles

Bgee: expression breadth ubiquitous, 299 present calls, max score 97.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.3851 / max 178.4977, expressed in 1795 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155135	14.3750	1795
155136	0.0101	3

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	97.32	gold quality
male germ cell	CL:0000015	96.59	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.34	gold quality
amniotic fluid	UBERON:0000173	95.88	gold quality
gingival epithelium	UBERON:0001949	94.54	gold quality
palpebral conjunctiva	UBERON:0001812	94.43	gold quality
germinal epithelium of ovary	UBERON:0001304	94.11	gold quality
cortical plate	UBERON:0005343	93.99	gold quality
eye	UBERON:0000970	93.89	gold quality
gingiva	UBERON:0001828	93.72	gold quality
substantia nigra pars compacta	UBERON:0001965	93.55	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.53	gold quality
pons	UBERON:0000988	93.52	gold quality
right testis	UBERON:0004534	92.91	gold quality
middle temporal gyrus	UBERON:0002771	92.71	gold quality
left testis	UBERON:0004533	92.66	gold quality
primary visual cortex	UBERON:0002436	92.65	gold quality
ganglionic eminence	UBERON:0004023	92.39	gold quality
testis	UBERON:0000473	92.31	gold quality
pigmented layer of retina	UBERON:0001782	92.29	gold quality
retina	UBERON:0000966	92.27	gold quality
islet of Langerhans	UBERON:0000006	92.23	gold quality
substantia nigra pars reticulata	UBERON:0001966	91.94	gold quality
occipital lobe	UBERON:0002021	91.82	gold quality
medial globus pallidus	UBERON:0002477	91.74	gold quality
esophagus squamous epithelium	UBERON:0006920	91.67	gold quality
placenta	UBERON:0001987	91.55	gold quality
superior vestibular nucleus	UBERON:0007227	91.41	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.34	gold quality
globus pallidus	UBERON:0001875	91.26	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.19
E-MTAB-7303	no	319.81

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

114 targeting ATMIN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-374B-5P	99.90	69.98	2734

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 15.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 21)

• ASCIZ acts as a lesion-specific focus scaffold in a Rad51-dependent pathway that resolves cytotoxic repair intermediates, most likely single-stranded DNA gaps, resulting from MLH1-dependent processing of base lesions. (PMID:15933716)
• ATM/ATR-Substrate Chk2-Interacting Zn2+-finger protein (ASCIZ) required for repair of abasic sites after methylating and oxidative DNA damage but not double-strand breaks. Forms DNA damage-induced foci with RAD51 and ssDNA. ASCIZ foci depend on MLH1. (PMID:15933716)
• ATMIN defines a novel NBS1-independent pathway of ATM signalling. (PMID:17525732)
• These data suggest that ASCIZ may affect the choice between competing base repair pathways in a manner that reduces the amount of substrates available for Ig gene conversion. (PMID:18433721)
• ASCIZ (ATMIN) is structurally related to the yeast ATM/ATR substrate Mdt1 (Pin4/Ybl051c); both proteins contain SQ/TQ cluster domains and interact with N-terminal FHA domains of CHK2/Rad53 kinases. (PMID:18728389)
• Absence of Asciz (Atmin) leads to increased oxidative and methylating DNA base damage sensitivity in primary fibroblasts (PMID:20975950)
• Asciz (Atmin) deletion or knock-down does not affect ATM levels and activation in mouse, chicken, or human cells (PMID:20975950)
• these results imply a potential cellular interference between DYNLL1 and ATMIN functions. (PMID:21971545)
• The ASCIZ-DYNLL1 feedback loop represents a novel mechanism for auto-regulation of gene expression, where the gene product directly inhibits the transcriptional activator while bound at its own promoter. (PMID:22167198)
• ATMIN is required for cell cycle progression and chromosome segregation following replication stress.ATMIN is required for the ATM-mediated signaling and recruitment of 53BP1 to DNA damage sites upon replication stress. (PMID:25262557)
• WRNIP1 connects PCNA monoubiquitination with ATMIN/ATM to activate ATM signalling in response to replication stress and contribute to the maintenance of genomic stability. (PMID:26549024)
• Repression of ATMIN in hypoxia is mediated by both p53 and HIF-1alpha in an oxygen dependent manner. (PMID:26875667)
• Studies suggest that ATM INteractor (ATMIN) could be an important biomarker in disease prognosis and treatment that might lighten the burden of chronic kidney disease and also affect on its progression. (PMID:27913685)
• The study results improve our understanding of the ATMIN-KRas axis leading to HNSCC migration or invasion and metastasis and facilitates the identification of possible therapy targets of downstream genes for designing effective therapeutic strategies in personalized medicine (PMID:28012797)
• ASCIZ/ATMIN is dispensable for ATM activation, and contradict the previously reported dependence of ATM on ASCIZ/ATMIN. (PMID:28648892)
• This work indicates a novel role for non-canonical Wnt/planar cell polarity signalling in Autosomal Recessive Polycystic Kidney Disease and suggests ATMIN as a modulator of PKHD1. (PMID:30414501)
• PPARgamma promotes ATM signaling and is essential for UBR5 activity targeting ATM interactor (ATMIN). (PMID:30699358)
• ATMIN is located close to FRA16D and is commonly lost in lung adenocarcinoma (LUAD)and was associated with reduced patient survival. ATMIN is a tumor suppressor in LUAD; fragility at chr16q23 correlates with loss of ATMIN in human LUAD. (PMID:31481498)
• ATMIN Suppresses Metastasis by Altering the WNT-Signaling Pathway via PARP1 in MSI-High Colorectal Cancer. (PMID:34148137)
• MicroRNA-361-5p slows down gliomas development through regulating UBR5 to elevate ATMIN protein expression. (PMID:34321465)
• Transcription factor ATMIN facilitates chemoresistance in nasopharyngeal carcinoma. (PMID:38321024)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	atmin	ENSDARG00000068601
mus_musculus	Atmin	ENSMUSG00000047388
rattus_norvegicus	AABR07043951.1	ENSRNOG00000011422

Paralogs (3): RIOK2 (ENSG00000058729), RIOK3 (ENSG00000101782), RIOK1 (ENSG00000124784)

Protein

Protein identifiers

ATM interactor — O43313 (reviewed: O43313)

Alternative names: ATM/ATR-substrate CHK2-interacting zinc finger protein, Zinc finger protein 822

All UniProt accessions (2): O43313, J3QRX7

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor. Plays a crucial role in cell survival and RAD51 foci formation in response to methylating DNA damage. Involved in regulating the activity of ATM in the absence of DNA damage. May play a role in stabilizing ATM. Binds to the DYNLL1 promoter and activates its transcription.

Subunit / interactions. Interacts via its C-terminus with ATM. Interacts with DYNLL1; this interaction inhibits ATMIN transcriptional activity and hence may play a role in a feedback loop whereby DYNLL1 inhibits transactivation of its own promoter by ATMIN.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitously expressed in normal tissues and cancer cell lines with highest levels in placenta and skeletal muscle.

Isoforms (2)

UniProt ID	Names	Canonical?
O43313-1	1	yes
O43313-2	2

RefSeq proteins (2): NP_001287657, NP_056066* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR055303	ATMIN	Family
IPR056380	Znf_C2H2_ASCIZ_4th	Domain
IPR056381	Znf_C2HC_ASCIZ_3rd	Domain
IPR056545	C2H2_ASCIZ_1st_2nd	Domain

Pfam: PF24757, PF24759, PF24761

UniProt features (23 total): sequence conflict 8, region of interest 5, compositionally biased region 4, zinc finger region 2, sequence variant 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43313-F1	47.67	0.01

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 162 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GCM_MAP4K4, TATTATA_MIR374, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, ONKEN_UVEAL_MELANOMA_UP, GOBP_CILIUM_ORGANIZATION, GOBP_DNA_DAMAGE_RESPONSE, GOBP_ORGANELLE_ASSEMBLY, GOBP_REGULATION_OF_CILIUM_ASSEMBLY, GOBP_MOTILE_CILIUM_ASSEMBLY, GOBP_CELL_PROJECTION_ORGANIZATION

GO Biological Process (7): regulation of transcription by RNA polymerase II (GO:0006357), DNA damage response (GO:0006974), positive regulation of gene expression (GO:0010628), motile cilium assembly (GO:0044458), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of non-motile cilium assembly (GO:1902857)

GO Molecular Function (7): transcription cis-regulatory region binding (GO:0000976), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), zinc ion binding (GO:0008270), dynein complex binding (GO:0070840), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), nuclear body (GO:0016604)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
cellular response to stress	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
cilium assembly	1
DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
positive regulation of cilium assembly	1
regulation of non-motile cilium assembly	1
non-motile cilium assembly	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
protein-containing complex binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nucleoplasm	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

936 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATMIN	ATM	Q13315	961
ATMIN	CHEK2	O96017	842
ATMIN	DYNLL1	P63167	793
ATMIN	UBR5	O95071	707
ATMIN	WRNIP1	Q96S55	544
ATMIN	NBN	O60934	479
ATMIN	RAD18	Q9NS91	434
ATMIN	TP53BP1	Q12888	434
ATMIN	NKX3-1	Q99801	424
ATMIN	UBR3	Q6ZT12	413
ATMIN	FAN1	Q9Y2M0	394
ATMIN	MDC1	Q14676	383
ATMIN	WWC1	Q8IX03	379
ATMIN	PRKDC	P78527	378
ATMIN	KAT7	O95251	371
ATMIN	MRNIP	Q6NTE8	371

IntAct

14 interactions, top by confidence:

A	B	Type	Score
DYNLL1	BLTP3B	psi-mi:“MI:0914”(association)	0.730
DYNLL2	BLTP3B	psi-mi:“MI:0914”(association)	0.640
ATM	ATMIN	psi-mi:“MI:0915”(physical association)	0.560
ATMIN	ATM	psi-mi:“MI:0915”(physical association)	0.560
ATM	ATMIN	psi-mi:“MI:0403”(colocalization)	0.560
BRAP	ATMIN	psi-mi:“MI:0915”(physical association)	0.370
ATMIN	OAS2	psi-mi:“MI:0914”(association)	0.350

BioGRID (23): ATMIN (Two-hybrid), WRNIP1 (Affinity Capture-Western), WRNIP1 (Affinity Capture-MS), CAPN13 (Affinity Capture-MS), SPECC1L (Affinity Capture-MS), ATMIN (Affinity Capture-RNA), ATMIN (Affinity Capture-Western), ATMIN (Affinity Capture-Western), ATMIN (Positive Genetic), OAS2 (Affinity Capture-MS), ATMIN (Affinity Capture-MS), ATMIN (Affinity Capture-MS), CAPN13 (Affinity Capture-MS), SPECC1L (Affinity Capture-MS), ATMIN (Affinity Capture-MS)

ESM2 similar proteins: A0A5K7RLP0, A1YEX3, A5GFT6, B8A5Y1, E1BKK0, F1LMN3, O35914, O43313, O88850, P24278, P86174, P97303, Q01954, Q12766, Q14B70, Q17R98, Q3ULM6, Q498S6, Q505G8, Q5RC05, Q5RDQ6, Q5W0Q7, Q68FE9, Q69ZB8, Q6A098, Q6P9S1, Q6ZPY5, Q6ZU67, Q6ZVT6, Q7Z4V0, Q8BFU3, Q8BHZ4, Q8CCH7, Q8IW35, Q8ND24, Q8TCN5, Q8VHI4, Q8VIG2, Q8WW38, Q91YE5

Diamond homologs: B1B534, B8BGV5, F4IPE3, F4JYZ8, O22759, O43313, Q0WT24, Q2QX40, Q6P9S1, Q700D2, Q8GYC1, Q8H1F5, Q8RWX7, Q8VWG3, Q8W030, Q8W031, Q943I6, Q944L3, Q9C8N5, Q9C9X7, Q9FFH3, Q9FRH4, Q9FX68, Q9LRW7, Q9LVQ7, Q9SCQ6, Q9SGD1, Q9SVY1, Q9ZUL3, Q9ZWA6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

178 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	154
Likely benign	10
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
584186	NC_000016.9:g.(?80623263)(81411221_?)del	Pathogenic
815850	GRCh37/hg19 16q23.2-23.3(chr16:80476611-82397606)x1	Likely pathogenic

SpliceAI

496 predictions. Top by Δscore:

Variant	Effect	Δscore
16:81036206:GGTG:G	donor_loss	1.0000
16:81036207:GTG:G	donor_loss	1.0000
16:81041350:TTGCA:T	acceptor_loss	1.0000
16:81041351:TGCA:T	acceptor_loss	1.0000
16:81041352:GCAG:G	acceptor_loss	1.0000
16:81041353:CAG:C	acceptor_loss	1.0000
16:81041441:GCCC:G	donor_gain	1.0000
16:81036208:T:G	donor_loss	0.9900
16:81041354:A:AG	acceptor_gain	0.9900
16:81041354:AG:A	acceptor_gain	0.9900
16:81041354:AGGAT:A	acceptor_gain	0.9900
16:81041355:G:GG	acceptor_gain	0.9900
16:81041355:GG:G	acceptor_gain	0.9900
16:81041355:GGAT:G	acceptor_gain	0.9900
16:81041355:GGATG:G	acceptor_gain	0.9900
16:81041477:AACAG:A	donor_loss	0.9900
16:81041478:ACAGG:A	donor_loss	0.9900
16:81041479:CAG:C	donor_loss	0.9900
16:81041480:AGGTA:A	donor_loss	0.9900
16:81041481:GG:G	donor_loss	0.9900
16:81041482:GTACT:G	donor_loss	0.9900
16:81041483:T:A	donor_loss	0.9900
16:81043159:AG:A	acceptor_gain	0.9900
16:81043160:GG:G	acceptor_gain	0.9900
16:81042523:G:T	donor_gain	0.9800
16:81043155:TTTCA:T	acceptor_loss	0.9800
16:81043156:TTCA:T	acceptor_loss	0.9800
16:81043157:TCAG:T	acceptor_loss	0.9800
16:81043158:CA:C	acceptor_loss	0.9800
16:81043159:A:AG	acceptor_gain	0.9800

AlphaMissense

5413 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:81036126:T:A	C86S	1.000
16:81036126:T:C	C86R	1.000
16:81036127:G:A	C86Y	1.000
16:81036127:G:C	C86S	1.000
16:81036128:C:G	C86W	1.000
16:81036180:C:G	H104D	1.000
16:81036182:C:A	H104Q	1.000
16:81036182:C:G	H104Q	1.000
16:81042283:C:A	H155Q	1.000
16:81042283:C:G	H155Q	1.000
16:81042317:T:C	C167R	1.000
16:81042326:T:A	C170S	1.000
16:81042326:T:C	C170R	1.000
16:81042327:G:C	C170S	1.000
16:81042357:T:C	L180P	1.000
16:81036127:G:T	C86F	0.999
16:81036154:T:A	L95Q	0.999
16:81036172:T:A	L101H	0.999
16:81036172:T:C	L101P	0.999
16:81036178:T:C	M103T	0.999
16:81036180:C:A	H104N	0.999
16:81036181:A:G	H104R	0.999
16:81036184:T:C	L105P	0.999
16:81036189:A:G	K107E	0.999
16:81036191:G:C	K107N	0.999
16:81036191:G:T	K107N	0.999
16:81036195:C:G	H109D	0.999
16:81036197:C:A	H109Q	0.999
16:81036197:C:G	H109Q	0.999
16:81041410:T:G	Y131D	0.999

dbSNP variants (sampled 300 via entrez): RS1000208492 (16:81035723 C>T), RS1000710888 (16:81047836 A>G), RS1000878749 (16:81039857 G>T), RS1000928831 (16:81037271 T>A,C,G), RS1001231457 (16:81035569 C>G), RS1001304706 (16:81040642 G>A), RS1001470193 (16:81036369 C>T), RS1001714675 (16:81047241 T>C), RS1001766852 (16:81047482 A>G), RS1002223275 (16:81037331 C>T), RS1002237196 (16:81036930 G>A), RS1002439364 (16:81042013 C>A,T), RS1002477674 (16:81037151 C>A,T), RS1002711242 (16:81041768 G>A,C,T), RS1002856367 (16:81034512 CA>C,CAA)

Disease associations

OMIM: gene MIM:614693 | disease phenotypes: MIM:256850

GenCC curated gene-disease

Mondo (1): giant axonal neuropathy 1 (MONDO:0009749)

Orphanet (1): Giant axonal neuropathy (Orphanet:643)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004602_281	Mean corpuscular volume	1.000000e-10
GCST005958_20	Waist-to-hip ratio adjusted for BMI (age >50)	4.000000e-06
GCST005962_30	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	1.000000e-06
GCST90002390_95	Mean corpuscular hemoglobin	1.000000e-11
GCST90002392_511	Mean corpuscular volume	7.000000e-15

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004527	mean corpuscular hemoglobin

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	3
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
di-n-butylphosphoric acid	affects expression	1
deguelin	decreases expression	1
fenpyroximate	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
pyrimidifen	decreases expression	1
Sunitinib	increases expression	1
Leflunomide	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Antimycin A	decreases expression	1
Benzo(a)pyrene	increases expression	1
Cadmium	decreases expression	1
Doxorubicin	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Ozone	increases abundance, affects expression	1
Rotenone	decreases expression	1
Selenium	increases expression, decreases expression, affects cotreatment	1
Dihydrotestosterone	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Vitamin E	affects cotreatment, increases expression, decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Cyclosporine	decreases expression	1
Cadmium Chloride	decreases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

1 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03333200	Not specified	RECRUITING	Longitudinal Study of Neurodegenerative Disorders